Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study

Blood (2024) 144 (Supplement 1): 1631.

https://doi.org/10.1182/blood-2024-200018

Published: 2024

Journal Articles

Immune Graft Composition Is Important for Deepening Response and Outcome after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma Who Do Not Receive Maintenance Therapy

Yeasung Lee, Francesca Bladt, Dimitrios Leonardos, Chira Mustafa, Alexia Katsarou, Maria Atta, Marco Bua, Ian Gabriel, Jose Ros-Soto, Alexandra Bazeos, Jiri Pavlu, Sandra Loaiza, Emma Bray, Farah O'Boyle, Elisabet Nadal, Richard Szydlo, Nicholas Crump, Anastasios Karadimitris, Aristeidis Chaidos

Blood (2023) 142 (Supplement 1): 759.

https://doi.org/10.1182/blood-2023-188912

Published: 2023

Journal Articles

Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results

Blood (2023) 142 (Supplement 1): 858.

https://doi.org/10.1182/blood-2023-173953

Published: 2023

Journal Articles

Characterizing Diffuse Large B Cell Lymphoma (DLBCL) Disease Biology Features and Survival Outcomes By Patient Racial Groups Using Real World Data

Hwai Jing Hiew, Yutong Liu, Spencer James, Sandhya Balasubramanian, Alexandra Bazeos, Yanrong Jiang

Blood (2022) 140 (Supplement 1): 9528–9529.

https://doi.org/10.1182/blood-2022-159423

Published: 2022

Journal Articles

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Blood (2021) 137 (5): 600–609.

https://doi.org/10.1182/blood.2020006578

Published: 2021

Includes: Supplemental data

Journal Articles

Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL

Eugene C Kim, PhD, Jinzhen Fan, PhD, Christopher R Bolen, PhD, Alexandra Bazeos, MD PhD FRCPath, Yanwen Jiang, PhD, Sandhya Balasubramanian, MS, Rama Balakrishnan, PhD, Andrea Knapp, PhD, Kathryn Humphrey, BSc, Tina G Nielsen, MD PhD, Jeffrey M. Venstrom, MD PhD, Genevive Hernandez, PhD, Joseph N Paulson, PhD

Blood (2019) 134 (Supplement_1): 2788.

https://doi.org/10.1182/blood-2019-124687

Published: 2019

Journal Articles

Low Peripheral Blood NK Cell Count Is Associated with Worse Clinical Outcome in Patients with Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results from the Frontline Phase 3 GALLIUM and GOYA Trials

Magdalena Klanova, MD, Mikkel Z. Oestergaard, Marek Trněný, MD PhD, Wolfgang Hiddemann, MD PhD, Robert Marcus, Laurie H. Sehn, MDMPH, Umberto Vitolo, MD, Alexandra Bazeos, Valentin Goede, MD, Harald Zeuner, Andrea Knapp, Denis Sahin, Nathalie Danesi, Christopher Bolen, Susan Robson, Jeffrey M. Venstrom, Tina Nielsen, Günter Fingerle-Rowson

Blood (2017) 130 (Supplement 1): 727.

https://doi.org/10.1182/blood.V130.Suppl_1.727.727

Published: 2017

Journal Articles

Mode of Progression after First Line Treatment Correlates with Outcome of Chronic Lymphocytic Leukemia (CLL)

Othman Al-Sawaf, MD, Alexandra Bazeos, Sandra Robrecht, PhD, Jasmin Bahlo, PhD, Anna Maria Fink, MD, Julia Von Tresckow, Paula Cramer, MD, Petra Langerbeins, MD, Nadine Kutsch, MD, Kathryn Humphrey, PhD, Günter Fingerle-Rowson, MD PhD, Stephan Stilgenbauer, MD PhD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Barbara F. Eichhorst, MD, Michael Hallek, MD, Valentin Goede, MD

Blood (2017) 130 (Supplement 1): 1740.

https://doi.org/10.1182/blood.V130.Suppl_1.1740.1740

Published: 2017

Journal Articles

Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy

Georgios Nteliopoulos, MSc, PhD, Alexandra Bazeos, MB, BS, MRCP, Gareth Gerrard, PhD, Simone Claudiani, MD, Ed Curry, PhD, Mary Alikian, MSc, PhD, Hui En Foong, Letizia Foroni, MD PhD FRCPath, Jane F. Apperley, MD

Blood (2016) 128 (22): 1223.

https://doi.org/10.1182/blood.V128.22.1223.1223

Published: 2016

Journal Articles

Evaluation of Fatigue in Previously Untreated CLL Patients with Comorbidities Treated with Obinutuzumab (GA101) + Chlorambucil (GClb) or Rituximab + Chlorambucil (RClb)

Valentin Goede, MD, Peter C Trask, Katharina Ziesel, Marianne Uguen, MSc, Alexandra Bazeos, Kirsten Fischer, MD, Michael Hallek, MD

Blood (2016) 128 (22): 2401.

https://doi.org/10.1182/blood.V128.22.2401.2401

Published: 2016

Journal Articles

Progression By Lymphocytosis Correlates with Favourable Long-Term Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL)

Alexandra Bazeos, Craig Gower, Francine Swann, Peter C Trask, Mark Dixon, BSc MSC, Noelle Crompton, Nelson Kinnersley, Othman Al-Sawaf, MD, Valentin Goede, MD, Günter Fingerle-Rowson, Kathryn Humphrey, PhD

Blood (2016) 128 (22): 4352.

https://doi.org/10.1182/blood.V128.22.4352.4352

Published: 2016

Journal Articles

Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling

Blood (2013) 122 (2): 227–238.

https://doi.org/10.1182/blood-2012-11-465039

Published: 2013

Includes: Supplemental data

Journal Articles

Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,

Blood (2011) 118 (21): 3753.

https://doi.org/10.1182/blood.V118.21.3753.3753

Published: 2011

Journal Articles

BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML.

Alexandra Bazeos, David Marin, Gareth Gerrard, PhD, Richard Szydlo, Dragana Milojkovic, MD, Alistair Reid, Hugues de Lavallade, Jane F. Apperley, MBChB, FRCP, FRCPath, John M Goldman, DM, FCRP, FRCPath, Letizia Foroni, Jamshid Sorouri Khorashad, MD

Blood (2009) 114 (22): 3248.

https://doi.org/10.1182/blood.V114.22.3248.3248

Published: 2009

NARROW

Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study

Immune Graft Composition Is Important for Deepening Response and Outcome after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma Who Do Not Receive Maintenance Therapy

Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results

Characterizing Diffuse Large B Cell Lymphoma (DLBCL) Disease Biology Features and Survival Outcomes By Patient Racial Groups Using Real World Data

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL

Low Peripheral Blood NK Cell Count Is Associated with Worse Clinical Outcome in Patients with Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results from the Frontline Phase 3 GALLIUM and GOYA Trials

Mode of Progression after First Line Treatment Correlates with Outcome of Chronic Lymphocytic Leukemia (CLL)

Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy

Evaluation of Fatigue in Previously Untreated CLL Patients with Comorbidities Treated with Obinutuzumab (GA101) + Chlorambucil (GClb) or Rituximab + Chlorambucil (RClb)

Progression By Lymphocytosis Correlates with Favourable Long-Term Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL)

Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling

Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,

BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only